Literature DB >> 29275380

Double hit! A unique case of resistant hypertension.

Kristen Elizabeth DeCarlo1, Nidhi Agrawal2.   

Abstract

A middle-aged woman with obesity, hyperlipidaemia and diet-controlled diabetes was referred for resistant hypertension. Her blood pressure (BP) was uncontrolled on five medications, including a diuretic. Physical exam revealed a systolic ejection murmur, and ECHO demonstrated moderate hypertrophy. Laboratory examination revealed elevated aldosterone level (20.7 ng/dL) and elevated aldosterone:renin ratio (41.4 (ng/dL)/(ng/mL/h)), meeting criteria for primary aldosteronism (PA), and confirmed by saline infusion testing. CT scan of the adrenals was non-localising. Adrenal venous sampling confirmed bilateral idiopathic adrenal hyperplasia. Concurrent primary hyperparathyroidism was demonstrated by elevated calcium and parathyroid hormone levels and localised by sestamibi scan. Idiopathic adrenal hyperplasia was treated medically with spironolactone. Her BP remained elevated until postparathyroidectomy. Evidence shows that a hyperfunctioning parathyroid gland may contribute to maintaining hyperaldosteronism in PA making this bidirectional link unique. The significance of this case is in the potential for further understanding of the pathophysiology of common causes of secondary hypertension. © BMJ Publishing Group Ltd (unless otherwise stated in the text of the article) 2017. All rights reserved. No commercial use is permitted unless otherwise expressly granted.

Entities:  

Keywords:  adrenal disorders; drugs: endocrine system; endocrinology; hypertension

Mesh:

Substances:

Year:  2017        PMID: 29275380      PMCID: PMC5780592          DOI: 10.1136/bcr-2017-221530

Source DB:  PubMed          Journal:  BMJ Case Rep        ISSN: 1757-790X


  24 in total

1.  Is there an unrecognized epidemic of primary aldosteronism? Con.

Authors:  Norman M Kaplan
Journal:  Hypertension       Date:  2007-09       Impact factor: 10.190

2.  PTH and PTH-related peptide enhance steroid secretion from human adrenocortical cells.

Authors:  G Mazzocchi; F Aragona; L K Malendowicz; G G Nussdorfer
Journal:  Am J Physiol Endocrinol Metab       Date:  2001-02       Impact factor: 4.310

3.  Primary aldosteronism with concurrent primary hyperparathyroidism: clinical case load in a single centre.

Authors:  A Concistré; L Petramala; L Zinnamosca; A Settevendemmie; F Corpaci; C Marinelli; G F Tonnarini; G D'Ermo; G De Toma; C Letizia
Journal:  Eur Rev Med Pharmacol Sci       Date:  2015       Impact factor: 3.507

4.  Relationship between serum parathyroid hormone levels in the elderly and 24 h ambulatory blood pressures.

Authors:  L Morfis; P Smerdely; L G Howes
Journal:  J Hypertens       Date:  1997-11       Impact factor: 4.844

5.  Cardiovascular disease, hypertension and renal function in primary hyperparathyroidism.

Authors:  G M Hedbäck; A S Odén
Journal:  J Intern Med       Date:  2002-06       Impact factor: 8.989

6.  Mild hyperparathyroidism: a novel surgically correctable feature of primary aldosteronism.

Authors:  Carmela Maniero; Ambrogio Fassina; Teresa M Seccia; Antonio Toniato; Maurizio Iacobone; Mario Plebani; Raffaele De Caro; Lorenzo A Calò; Achille C Pessina; Gian P Rossi
Journal:  J Hypertens       Date:  2012-02       Impact factor: 4.844

7.  A prospective study of the prevalence of primary aldosteronism in 1,125 hypertensive patients.

Authors:  Gian Paolo Rossi; Giampaolo Bernini; Chiara Caliumi; Giovambattista Desideri; Bruno Fabris; Claudio Ferri; Chiara Ganzaroli; Gilberta Giacchetti; Claudio Letizia; Mauro Maccario; Francesca Mallamaci; Massimo Mannelli; Mee-Jung Mattarello; Angelica Moretti; Gaetana Palumbo; Gabriele Parenti; Enzo Porteri; Andrea Semplicini; Damiano Rizzoni; Ermanno Rossi; Marco Boscaro; Achille Cesare Pessina; Franco Mantero
Journal:  J Am Coll Cardiol       Date:  2006-11-13       Impact factor: 24.094

8.  Serum parathyroid hormone level is associated with body mass index. The 5th Tromsø study.

Authors:  Elena Kamycheva; Johan Sundsfjord; Rolf Jorde
Journal:  Eur J Endocrinol       Date:  2004-08       Impact factor: 6.664

9.  Effect of eplerenone on parathyroid hormone levels in patients with primary hyperparathyroidism: results from the EPATH randomized, placebo-controlled trial.

Authors:  Andreas Tomaschitz; Nicolas Verheyen; Andreas Meinitzer; Burkert Pieske; Evgeny Belyavskiy; Helmut Brussee; Josef Haas; Winfried März; Elisabeth Pieske-Kraigher; Sarah Verheyen; Lisa Ofner-Ziegenfuss; Bríain Ó Hartaigh; Verena Schwetz; Felix Aberer; Martin Grübler; Florian Lang; Ioana Alesutan; Jakob Voelkl; Martin Gaksch; Jörg H Horina; Hans-Peter Dimai; Jutta Rus-Machan; Claudia Stiegler; Eberhard Ritz; Astrid Fahrleitner-Pammer; Stefan Pilz
Journal:  J Hypertens       Date:  2016-07       Impact factor: 4.844

Review 10.  Aldosterone and parathyroid hormone: a precarious couple for cardiovascular disease.

Authors:  Andreas Tomaschitz; Eberhard Ritz; Burkert Pieske; Astrid Fahrleitner-Pammer; Katharina Kienreich; Jörg H Horina; Christiane Drechsler; Winfried März; Michael Ofner; Thomas R Pieber; Stefan Pilz
Journal:  Cardiovasc Res       Date:  2012-02-13       Impact factor: 10.787

View more
  1 in total

1.  Systolic heart failure in a patient with primary aldosteronism.

Authors:  Chikezie Alvarez; Vinuta Mohan
Journal:  BMJ Case Rep       Date:  2018-06-08
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.